IMCY-0098, a modified peptide developed from human proinsulin, is able to target and eliminate pathogenic T cells in newly diagnosed T1DM, thereby preserving pancreatic β-cells and improving glycemic control (NCT03272269) 49. The gene discussed is INS; the disease is type 1 diabetes mellitus.